An Early Test Of Antitrust Ramifications Of FDA's REMS
On Dec. 22, 2014, a federal district court in New Jersey found that Mylan Pharmaceuticals Inc. alleged facts sufficient to plead an antitrust claim under Section 2 of the Sherman Act...To view the full article, register now.
Already a subscriber? Click here to view full article